Content Type: Article

  • Energy efficiency in the building sector – an overview of the legal measures

    Energy efficiency in the building sector – an overview of the legal measures

    ARTICLE

    Energy efficiency in the building sector – an overview of the legal measures

    April 24, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The German government’s new solar package, the EU Commission’s new emissions reduction targets, mandatory refurbishment and solar obligations for building owners, climate-neutral heating, CO2 levies, etc. – the building sector is constantly the subject of national and European debate due to its important role in the climate transition. In this article, Michelle Leverkus and Thomas Beisken summarize which European and national regulations you, as the owner of existing properties and project developments, need to pay particular attention to and keep an eye on.

    In depth
    Authors

    Thomas A. Beisken, LL.M.

    Partner

    Düsseldorf

    More insights

  • How the Utah Artificial Intelligence Policy Act Impacts Health Professionals

    How the Utah Artificial Intelligence Policy Act Impacts Health Professionals

    ARTICLE / CLIENT ALERT

    How the Utah Artificial Intelligence Policy Act Impacts Health Professionals

    April 23, 2024

    Read time: 9 min

    Key takeaways
    Overview

    On March 13, 2024, Utah Governor Spencer Cox signed Utah State S.B. 149, the Artificial Intelligence Policy Act (the AI Act) into law, which amends the Utah consumer protection and privacy laws to require disclosure, in certain circumstances, of artificial intelligence (AI) use to consumers, effective May 1, 2024. Interestingly, the AI Act takes a bifurcated approach to the disclosure requirement. The law holds businesses and individuals at large to one standard, and it holds regulated occupations, including healthcare professionals, to another standard. The AI Act does not require individuals’ consent or directly regulate how generative AI is used once it is disclosed to patients.

    Key Takeaways

    • While Utah’s AI Act requires disclosure of AI use to general consumers only if asked, the law requires regulated professionals (such as physicians) to prominently disclose the use of AI in advance.
    • The AI Act’s definition of “generative AI” is vaguely and broadly worded and may include solutions beyond those typically considered generative AI.
    • The Office of Artificial Intelligence Policy’s AI learning laboratory program allows AI developers and deployers to benefit from regulatory mitigation, including waived civil fines, during pilot testing.

    Alongside nascent efforts at the federal level to consider regulatory approaches to the development and deployment of AI, an increasing number of state regulatory bodies, including legislatures and professional boards, are entering the fray. Utah is the latest state to endeavor to craft a regulatory response to AI. While many states have enacted laws that impact the deployment of AI tools, including more robust data privacy requirements, few have specifically addressed the deployment of AI tools, and none have specifically focused on the deployment of generative AI tools.

    In depth

    Bifurcated AI Use Disclosure Requirements

    Commercial Use of AI Under Utah Law

    The AI Act requires anyone that deploys generative AI to interact with a person in a manner that is regulated under Utah consumer privacy laws to disclose the use of AI clearly and conspicuously, but only if asked or prompted by the consumer. The AI will need to be trained to confirm that it is AI when asked, and AI deployers will otherwise need to respond to requests for information from consumers. Furthermore, AI deployers likely cannot place the disclosure in terms and conditions because the law requires clear and conspicuous disclosure.

    Health Professional Use of AI Under Utah Law

    Conversely, the AI Act requires regulated professionals, such as physicians, to “prominently” disclose the use of generative AI in advance of its use. The disclosure should be provided verbally at the start of an oral exchange or conversation and through electronic messaging before a written exchange.

    The AI Act leaves the practitioner to determine what the disclosure should include and how much detail to provide. The AI Act is also unclear on how often disclosure is required (i.e., whether disclosure of the use of generative AI should come before each instance of its use, or only before the first instance by a particular regulated professional or organization with which the professional is associated with respect to a particular patient or other consumer). Finally, while the legislation is clear that these disclosure obligations apply where generative AI is used while providing the regulated service (e.g., the practice of medicine), it is often unclear when professional services begin and end. For example, regulated healthcare professionals may struggle to determine whether they are engaging in licensed activity (e.g., the practice of medicine) in a number of circumstances such as care coordination, record management, data analysis and other broad-based activities that are increasingly common in value-based care environments.

    While the emphasis on public transparency has benefits, laws such as the AI Act present a few challenges to professionals seeking to achieve meaningful transparency. For example, many patients of regulated healthcare professionals will not understand how sophisticated AI technology works. Accordingly, if a patient has a question about the AI solution and the professional does not know the answer, the dynamic relationship between the professional and patient could be undermined. Further, healthcare professionals do not routinely disclose all technology to be used during a course of treatment, and the AI Act will likely prompt patients to ask questions of this technology in particular. The rationale for treating generative AI technology differently than, for example, an MRI, is not clear.

    Which Approach Applies to You?

    As a result of the bifurcated approach to governing AI disclosure requirements, AI deployers will need to evaluate which requirement applies to them. Technically, the law delineates between (a) “regulated occupations,” which include healthcare professionals, and (b) all others who “use, prompt, or otherwise cause generative artificial intelligence to interact with a [consumer] ….” The definition of “regulated occupations” includes all occupations regulated and licensed by the Utah Department of Commerce. This definition includes licensed individuals like physicians, but it is not clear whether the disclosure requirement applies to nonlicensed employees or co-workers acting on behalf of the professional. The second prong of the disclosure portion of the AI Act has broader application, which can result in seemingly inconsistent applications. For example, in the value-based care space, companies may use AI to help guide patients in making triage decisions. Such a use would only be subject to the broader requirement to disclose the use of AI if the consumer asks for the disclosure. However, when a physician uses AI in a similar manner to interact with a patient and help the patient understand his or her symptoms to offer diagnostic input, such use would be subject to the regulated occupation requirement to disclose the AI use at the outset. While these cases are very similar on their face, the AI Act treats them rather differently.

    Definition of Generative AI

    The AI Act defines “generative AI” as “an artificial system that: is trained on data; interacts with a person using text, audio, or visual communication; and generates non-scripted outputs similar to outputs created by a human, with limited or no human oversight.” While the definition includes some ambiguous terms, it contains the essential elements of what is commonly understood to be generative AI. Nonetheless, it does involve some confusing and perhaps poorly considered aspects.

    For example, the third element of the definition vaguely describes a pseudo-objective standard around the outputs by reference to outputs created by a human. When considering the breadth of the communication methodologies humans use, this would likely capture every output imaginable, from a simple text message to graphs and charts to artistic expression. However, the other elements are likely otherwise generic enough for the definition to capture just about any machine learning-developed automated system. Thus, while the AI Act correctly and implicitly acknowledges that generative AI, as opposed to nongenerative AI, presents more risks and more potential sensitivities for consumers, the differentiating definition may be hard to implement and may inadvertently capture AI tools that do not raise the kinds of concerns the AI Act is trying to address.

    Enforcement and Liability

    The AI Act states that when the use of generative AI is not preceded by proper disclosure, the use violates Utah consumer protection laws, which can result in civil penalties of up to $5,000 per violation in enforcement actions brought by the Utah Attorney General. In such cases, AI deployers, as applicable, are liable for the violation and subject to corresponding penalties. The AI Act provides that a party violating the disclosure requirement cannot avoid liability by claiming that the generative AI “made the violative statement; undertook the violative act; or was used in furtherance of the violation.” This provision undermines a generative AI tool deployer’s ability to defend against a claim of violation by stating that the developer of the technology is responsible, and it may also work to undermine the argument that a generative AI tool has enough independent agency to be recognized as an independent actor. However, an AI deployer could seek to hold a developer liability through indemnities or other contractual risk allocation provisions.

    Rulemaking Authority and Mitigation

    While other states have created sub-agencies or focus groups to study AI, under the AI Act, the Utah Office of Artificial Intelligence Policy will essentially be a proving ground for effective AI policy and technologies. The AI Act also creates a regulatory agency called the Office of Artificial Intelligence Policy. The Office of Artificial Intelligence Policy was created to administer the AI learning laboratory program and to engage with stakeholders about potential regulatory developments in the field. The AI learning laboratory will assess AI technologies to inform state regulatory frameworks, encourage AI development in the state and assist in the evaluation of proposed regulatory structures. Significantly, the AI learning laboratory will allow participants who join the laboratory to test their products.

    Participants in the AI laboratory program may apply for regulatory mitigation during pilot testing, which will allow them to test their AI products in the real world without compliance concerns. This feature of the AI laboratory program is particularly important given the fast-changing nature of AI and the uncertainty around each new use case. Further, the Office of Artificial Intelligence Policy has rulemaking authority to impose rules and requirements for the use of AI products for AI laboratory program participants. Through this rulemaking authority, the Office will likely create a more tangible definition of regulatory mitigation in the AI context.

    Our cross-practice team continues to closely monitor developments in AI. Reach out to one of the authors of this On the Subject or your regular McDermott lawyer to discuss the potential legal implications for your business.

    Authors

    Daniel F. Gottlieb

    Partner

    Chicago

    Jennifer S. Geetter

    Partner

    Washington, DC

    Reuben Bank

    Associate

    Los Angeles

    More insights

  • Litigation Value in Nullity Proceedings re Formulation Patents

    Litigation Value in Nullity Proceedings re Formulation Patents

    ARTICLE

    Litigation Value in Nullity Proceedings re Formulation Patents

    April, 23 2024

    Read time: 2 min

    Key takeaways
    Overview

    In a recent decision of the Federal Court of Justice (BGH) dated January 23, 2024 (case reference: X ZR 161/23), the determination of the value in dispute in patent nullity proceedings was discussed. More information can be found in the article by Dr. Laura Katharina Woll, LL.M. and Lisa Nassi.

    In depth
    Authors
    More insights

  • China Draws Scrutiny as US Regulators Renew Anti-Bribery and Corruption Enforcement Focus

    China Draws Scrutiny as US Regulators Renew Anti-Bribery and Corruption Enforcement Focus

    ARTICLE / CLIENT ALERT

    China Draws Scrutiny as US Regulators Renew Anti-Bribery and Corruption Enforcement Focus

    April 22, 2024

    Read time: 7 min

    Key takeaways
    Overview

    Recent bribery and corruption enforcement efforts by the US Department of Justice (DOJ) and US Securities and Exchange Commission (SEC), combined with new legislative and policy initiatives, including last December’s passage of the Foreign Extortion Prevention Act (FEPA), signal a renewed focus on business activity abroad, particularly in China. And the data bears this point out, as China reclaimed its spot last year as the most frequently cited country in enforcement actions related to Foreign Corrupt Practices Act (FCPA) bribery schemes.

    Given the continuing prevalence of state-owned or controlled entities, China presents uniquely heightened anti-bribery and corruption challenges to companies operating or doing business in that jurisdiction. Such companies should carefully review their current anti-bribery and corruption policies, procedures, and internal controls and take proactive steps to ensure they meet or exceed the DOJ and SEC’s expectations.

    In depth

    Recent FCPA Enforcement Actions Connected to China

    As evidence of the DOJ’s and SEC’s clear and continued interest in China, four of the final six FCPA resolutions reached in 2023 involved conduct that occurred in, or was somehow connected to, China. And, more broadly, China was among the most frequently cited countries in connection with publicly disclosed FCPA-related investigations. Below we briefly summarize a few of the FCPA resolutions reached last year connected to China:

    1. Clear Channel Outdoor Holdings, Inc: On September 28, 2023, the SEC settled alleged FCPA violations against Clear Channel Outdoor Holdings, Inc. (Clear Channel), with Clear Channel agreeing to pay over $26 million in disgorgement and prejudgment interest. This resolution was spurred on by allegations that Clear Channel’s agent, a former majority-owned Chinese affiliate, paid bribes to a Chinese government official to obtain outdoor advertising contracts in violation of the FCPA’s anti-bribery, recordkeeping and internal accounting controls provisions.
    2. Albemarle Corporation: On September 29, 2023, the DOJ and SEC settled alleged FCPA violations against Albemarle Corporation (Albemarle), which agreed to pay over $218 million collectively, with $103 million in disgorgement and prejudgment interest to the SEC. The resolution was the by-product of allegations that Albemarle used agents who paid bribes to government officials in China, Vietnam, Indonesia, India and the United Arab Emirates in violation of the FCPA’s anti-bribery, recordkeeping and internal controls provisions.
    3. Koninklijke Philips N.V. On May 11, 2023, the SEC settled alleged FCPA violations against Koninklijke Philips N.V. (Philips), a medical device manufacturer. Philips agreed to pay a $62 million fine in connection with the operations of its subsidiaries in China, which supposedly had sought to improperly influence government hospital officials in violation of the FCPA’s books and records and internal accounting controls provisions.

    Recent Passage of FEPA

    In December 2023, the US Congress passed the FEPA, which makes it a federal crime for a foreign government official to solicit, demand or accept a bribe from a US company or citizen in exchange for taking (or omitting to take) official action or conferring an improper business advantage.

    Historically, US anti-corruption enforcement efforts have focused primarily on the “supply side” of foreign bribery, with the DOJ and SEC charging companies and individuals with violating the FCPA’s anti-bribery provisions by offering, promising or paying bribes to foreign officials. Although the DOJ has pursued the “demand side” of foreign bribery through other means – for example, by prosecuting corrupt foreign officials who receive bribes under anti-money laundering statutes – the FEPA provides for a new federal criminal offense that complements the FCPA’s anti-bribery provisions by targeting foreign officials who accept or solicit bribes.

    The enactment of the FEPA portends an uptick in US anti-corruption enforcement activity, particularly cases brought by the DOJ against foreign officials accused of corruptly receiving or soliciting bribes. The FEPA provides the DOJ with an additional enforcement tool to combat international corruption by focusing on foreign government officials who solicit or receive bribes where a sufficient US jurisdictional nexus exists. Rather than amending the FCPA, the FEPA establishes this new criminal offense by amending the domestic bribery statute codified at 18 U.S.C. § 201.

    Under the FEPA, a foreign government official can be held liable for corruptly demanding, seeking, receiving, accepting, or agreeing to receive or accept, directly or indirectly, anything of value from a covered person or entity “in return for being influenced to perform an official act, being induced to do or omit an act in violation of an official duty, or conferring any improper advantage in connection with obtaining or retaining business for or with, or directing business to, any person.”

    Several notable similarities and differences between the FEPA and the FCPA are worth highlighting:

    1. Jurisdictional nexus requirement: The FEPA defines the circumstances under which solicitations or demands for bribes have a sufficient US jurisdictional nexus, referencing the same general categories of individuals and entities subject to the FCPA’s jurisdiction. Specifically, the FEPA applies when a foreign official demands, seeks, receives or accepts a bribe from (1) “issuers” of US securities; (2) “domestic concerns” (i.e., US companies and persons); or (3) any person while in the territory of the US.
    2. Broader “foreign official” definition: While the FEPA largely adopts the definition of the term “foreign official” from the FCPA, the FEPA’s definition expressly extends to those acting in an “unofficial capacity for or on behalf of a government, department, agency, instrumentality, or a public international organization.” Moreover, unlike the FCPA’s definition of foreign officials, the FEPA’s also includes “senior foreign political figures.”
    3. No corresponding SEC jurisdiction: While the FEPA introduces this new criminal offense by amending the US’s existing domestic bribery law, the FEPA, unlike the FCPA, does not confer any civil enforcement authority to the SEC.
    4. Penalties: Statutory penalties for FEPA violations can range from (i) a fine of up to $250,000, or three times the value of the bribe, whichever is greater; and/or (ii) imprisonment of up to 15 years. By comparison, statutory penalties for individuals who violate the FCPA’s bribery violations can range from (i) a fine of up to $250,000, or twice the pecuniary gain or loss from the violation, and/or (ii) imprisonment of up to five years.

    Key Takeaways for Companies Doing Business in China

    • The passage of the FEPA and recent FCPA enforcement actions evidence the DOJ’s and SEC’s increased focus on aggressively combatting global corruption wherever it may occur, including in China, a frequently cited jurisdiction in alleged FCPA bribery schemes. Companies doing business or otherwise present in China should expect this continued focus regardless of any potential US administration change next year. Further, while the FEPA opens the door to criminal prosecution of foreign officials who accept or solicit bribes, practically speaking, it should not impact the DOJ’s interest in, and approach to, these types of matters.
    • The FEPA’s broader definition of “foreign officials” – and, in particular, its express reference to those acting in an “unofficial capacity” on behalf of a government, department, agency, instrumentality or a public international organization – likely signals an area of increased enforcement interest for the DOJ. Companies engaging with intermediaries or others who hold themselves out as unofficially connected to Chinese state-owned entities should carefully review those engagements, with an eye toward potential anti-corruption enforcement.
    • More generally, companies subject to US jurisdiction that do business or have a presence in China should continue to develop and maintain risk-based anti-bribery and corruption compliance programs. They should consistently monitor those programs so that they are in a position to timely amend and update their anti-bribery and corruption controls, particularly as to the onboarding and use of third parties abroad and government touchpoints.
    Authors

    Benton Curtis

    Partner

    Miami

    Peter Lu

    Partner

    London – 22 Bishopsgate

    Bradley A. Cohen

    Counsel

    New York – One Vanderbilt Avenue

    More insights

  • Consumer Sales Promotions: Overview (Germany)

    Consumer Sales Promotions: Overview (Germany)

    ARTICLE

    Consumer Sales Promotions: Overview (Germany)

    April 01, 2024

    Read time: 2 min

    Key takeaways
    Overview

    Promotional measures for consumers are subject to a series of laws and regulations. These laws and regulations govern not only the conduct of the promotion itself but also the way in which the promotion is advertised and how personal data may be collected, disclosed, and used. In the article “Consumer Sales Promotions: Overview (Germany)” by Dr. Boris Uphoff and Steffen Woitz, LL.M., published in Practical Law Global, they provide insights into the situation in Germany.

    In depth
    Authors

    Dr. Boris Uphoff

    Partner

    Munich, Düsseldorf

    More insights

  • A Guide to the New York LLC Transparency Act

    A Guide to the New York LLC Transparency Act

    ARTICLE / CLIENT ALERT

    A Guide to the New York LLC Transparency Act

    April 19, 2024

    Read time: 8 min

    Key takeaways
    Overview

    On March 1, 2024, New York Governor Kathy Hochul signed into law an amended version of the New York LLC Transparency Act (“NYLTA”),[1] requiring certain limited liability companies (“LLCs”) formed or authorized to do business in New York (each, a “NY Reporting Company”) to file a beneficial ownership information (“BOI”) report with the NY Department of State (“NY DOS”). Each NY Reporting Company will be required to disclose on its BOI report identifying information pertaining to each individual who directly or indirectly exercises substantial control or owns or controls 25 percent or more of the ownership interests of a NY Reporting Company (each, a “Beneficial Owner”) and the individuals involved in the NY Reporting Company’s formation or registration to do business in New York (each, an “Applicant”). Information reported to NY DOS will be maintained in a private database not accessible to the public. The NYLTA goes into effect on Jan. 1, 2026 and requires the NY DOS to promulgate regulations implementing the legislation.

    The NYLTA closely parallels the requirements of the Corporate Transparency Act (collectively, with its implementing regulations, the “CTA”)[2], the federal statute imposing similar requirements on certain legal entities known as “reporting companies,” and specifically incorporates a number of the CTA terms by reference. There are, however, important differences between the NYLTA and the CTA, as discussed below.

    Who is Impacted by the NYLTA?

    The NYLTA adopts the CTA’s definition of a “Reporting Company” but, unlike the CTA, which is applicable to all types of legal entities (e.g., LLCs, partnerships and statutory trusts), the NYLTA limits the definition of Reporting Company to LLCs formed or authorized to do business in New York state (“NY LLCs”). The NYLTA also incorporates the 23 exemptions to the definition of Reporting Company identified in the CTA. Accordingly, those NY LLCs that meet the definition of Reporting Company and do not qualify for at least one of the 23 enumerated exemptions identified in the CTA must file a NY BOI report. Unlike the CTA, the NYLTA requires LLCs that qualify for at least one of the 23 exemptions to file an attestation indicating the exemption being relied on.

    Other Key Terms

    Definition of Beneficial Owner. The NYLTA adopts the CTA’s definition of Beneficial Owner, which is broadly defined as any individual, who directly or indirectly (1) exercises substantial control[3] over the Reporting Company or (2) owns or controls 25 percent or more of the ownership interests[4] of the Reporting Company.

    Definition of Applicant. The NYLTA adopts the CTA’s definition of Applicant, which is an individual who: 1) directly files the document with a secretary of state or similar office that forms or registers the entity to do business in the US; and (2) is primarily responsible for directing or controlling the filing of the formation document or first registration document.

    What Information Must Be Reported?

    Each NY Reporting Company must include the following information regarding its Beneficial Owners and Applicants in its BOI report: (1) full legal name; (2) date of birth; (3) current home or business street address; and (4) a unique identifying number from an acceptable identification document (e.g., US driver’s license or US or foreign passport). While, under the CTA, individuals may obtain unique identifying numbers (i.e., FinCEN Identifiers) which may be provided to the Reporting Company in lieu of identifying information, under the NYLTA, there is no similar mechanism.

    BOI reports must be filed electronically in a “form and manner” directed by the NY DOS. In its implementing regulations, the NY DOS is expected to provide more information about the form to be used for the BOI reports and where the reports must be electronically filed.

    NY LLCs that are otherwise exempt from the definition of NY Reporting Company (e.g., fall within one of the 23 exemptions to the definition of CTA Reporting Company) must file an attestation of exemption indicating “the specific exemption claimed and the facts on which such exemption is based.” The NY DOS is expected to issue a form for this attestation of exemption, which must be signed and filed electronically under penalty of perjury. Under the CTA, there is no need to file any form indicating that the entity is exempt.

    Key Dates

    Effective Date: Jan. 1, 2026.

    Existing Entities. NY LLCs formed or authorized to do business in NY before January 1, 2026 must file their initial BOI report or attestation of exemption, as applicable, by January 1, 2027.

    New Entities. NY LLCs formed or authorized to do business in NY on or after January 1, 2026 must file a BOI report or attestation of exemption, as applicable, within 30 days of an initial filing of articles of organization or an application for authority.

    Annual Statement. All NY LLCs will be required to electronically file an annual statement with the NY DOS confirming or updating (1) BOI disclosure; (2) the street address of its principal executive office; (3) status as an exempt company, if applicable; and (4) any other information that may be required by the NY DOS. There is no similar requirement under the CTA to file an annual statement. In addition, unlike the CTA, the NYLTA does not require a NY Reporting Company to file an updated BOI report within 30 days of any change of BOI. However, the NYLTA does require a NY Reporting Company to correct any false or fraudulent BOI within 90 days of the filing and update any information as necessary in the annual statement.

    Who Will Have Access to BOI?

    The NY DOS will maintain the information of beneficial owners in a secure nonpublic database. The information will be confidential, but may be disclosed by NY DOS (1) pursuant to the written request or consent of the beneficial owner; (2) by court order; (3) to officers or employees of another federal, state or local government agency where disclosure is necessary for the agency to perform its official duties; or (4) for a valid law enforcement purpose. Recipients of BOI may not further disclose the information, except as authorized in law or as otherwise necessary for the performance of statutory duties. The NYLTA requires the NY DOS to establish provisions for sharing BOI with permitted agencies. Unlike the CTA BOI database, information maintained in the NY database will not be specifically available to designated financial institutions.

    Violations and Penalties

    Past Due and Delinquent Status. NY LLCs that fail to file a BOI report, an attestation of exemption or an annual statement for a period exceeding thirty days will be marked “past due” in NY DOS records. If a NY LLC is marked as past due for longer than two years, then it will be marked as “delinquent” in NY DOS records. For each day an NY LLC is past due or delinquent, the NY attorney general may assess a penalty of up to five hundred dollars. A past due or delinquent mark will be removed from NY DOS when the NY LLC files a BOI report, files an attestation of exemption or annual statement that it missed, pays a $250 fine or any other penalty imposed.

    For delinquent entities, the NY state attorney general may investigate and may bring an action to dissolve or annul a delinquent LLC that failed to file its BOI report or attestation of exemption.

    Suspension. In addition, where a NY LLC fails to file a BOI report or attestation of exemption, the NY LLC will also be suspended. Suspended entities will not be able to conduct business in NY until they file a BOI report or attestation of exemption. Once an entity files a BOI report or attestation of exemption, as applicable, the suspension will be annulled and all corporate powers, right, privileges, immunities, duties and liabilities will be restored.

    Fraudulent Disclosure. The NYLTA also makes it unlawful for any person to knowingly provide, or attempt to provide, false or fraudulent beneficial ownership information. The NY attorney general may bring an action to annul or dissolve any entity found to have provided false or fraudulent information. A person will not be found in violation of providing false or fraudulent disclosure, if (1) the person “voluntarily and promptly” provides corrected information within ninety days of the submission and (2) the person did not willfully submit the information to evade reporting requirements.

    Unlike the CTA, the NYLTA does not impose criminal penalties for failure to file a BOI report, an attestation of exemption or an annual statement, or for providing false or fraudulent information.

    Key Takeaways

    Corporate transparency has become a priority for the New York Legislature. LLCs that currently do business in New York or plan to do so in the future should expect increased scrutiny of their beneficial owners. To ensure compliance, NY LLCs should proactively review and determine the applicable filing requirements which will come due commencing Jan. 1, 2027. Companies should carefully examine whether the entities within their organizational structures fall within the definition of a NY Reporting Company or qualify for an exemption. When a NY LLC identifies entities within its structure that are NY Reporting Companies, NY LLCs should also identify the information required for prompt filing of initial NY BOI reports for the NY Reporting Companies, including any attestations of exemption. In addition, NY Reporting Companies will need to remember to file their annual statements as well. For assistance in navigating the complex reporting requirements of the CTA and NYLTA, please contact your attorney at Schulte Roth & Zabel.

    Authored by Melissa G.R. Goldstein, Betty Santangelo, Michael S. Didiuk, <Jessica Romano, Kyle B. Hendrix and Jonice Q. Jackson.


     

    [1] NY A.8544 / S.8059. The prior version of the NYLTA (NY A.3484-A / S.995-B) was amended by “chapter amendment,” which is an informal part of the New York legislative process allowing the governor to sign a bill with an agreement that the legislature will make certain amendments to the bill in the next legislative session.

    [2]  For a fuller discussion of the CTA, see our prior Alerts: (1) “Passage of Anti-Money Laundering Act of 2020 Includes Comprehensive BSA/AML Reform Measures”; (2) “The Corporate Transparency Act: The Private Funds Guide to Compliance With the Beneficial Ownership Reporting Rule”; (3) “The Corporate Transparency Act: Key Considerations for Compliance With the Beneficial Ownership Reporting Rule.”

    [3] An individual exercises “substantial control” if they: (1) are a senior officer of the Reporting Company (i.e., the president, chief financial officer, general counsel, chief executive officer, chief operating officer or any other officer, regardless of official title, who performs a similar function or has such authority as these officers); (2) have the ability to appoint or remove any senior officer or a majority the board of directors (or similar body) of the Reporting Company; (3) direct, determine or have substantial influence over important decisions made by the Reporting Company, including decisions regarding the Reporting Company’s business, finances and structure; or (4) have any other form of substantial control over the Reporting Company

    [4] Any individuals who own or control at least 25 percent of the “ownership interests” of the Reporting Company, which includes the five ownership interest types (1) equity, stock or voting rights; (2) capital or profit convertible instruments; (3) option or other non-binding; (4) privileges to buy or sell any of the foregoing; or (5) any other instruments, contract, arrangement, understanding, relationship or mechanism used to establish ownership.

    In depth
    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    Jonice Q. Jackson

    Associate

    Washington, DC

    More insights

  • Lessons from Ryan S. v. UnitedHealth Group for the 2023 MHPAEA proposed rule

    Lessons from Ryan S. v. UnitedHealth Group for the 2023 MHPAEA proposed rule

    ARTICLE

    Lessons from Ryan S. v. UnitedHealth Group for the 2023 MHPAEA proposed rule

    April 18, 2024

    Read time: 6 min

    A recently decided US Court of Appeals for the Ninth Circuit case, Ryan S. v. UnitedHealth Group, Inc., offers some useful insights on the enforcement by private litigants of the Mental Health Parity and Addiction Equity Act (MHPAEA). Like other similar cases, the case invites questions about the impact of potential changes under the proposed regulations issued under MHPAEA last year. Despite that the issues at this stage are procedural, the case nevertheless offers some useful insights, which this post explores.

    According to the complaint, the group health plan under which Ryan S. was covered was administered by UnitedHealthcare. The plan covered outpatient, out-of-network mental health and substance use disorder (MH/SUD) benefits at 70% of covered charges and at 100% once the out-of-pocket maximum was met.

    Ryan S. completed two different outpatient, out-of-network substance use disorder programs, coverage for which was denied on multiple occasion and for disparate reasons. As the complaint explains, the denials resulted from UnitedHealthcare’s use of an algorithm that assessed patients’ progress and referred cases for additional review. This additional layer of review was not applied to outpatient, out-of-network medical/surgical (M/S) claims. Ryan S. alleges that UnitedHealthcare applied a more stringent review process to benefits claims for outpatient, out-of-network MH/SUD treatment than to otherwise comparable M/S treatment. The complaint states this disparity in applicable review standards violates:

    • MHPAEA
    • The Employee Retirement Income Security Act (ERISA) fiduciary rules
    • The failure to follow the terms of the plan as required by ERISA

    The Disposition of the Plaintiffs’ Claims

    The district court had dismissed all the claims. The Ninth Circuit reversed on MHPAEA and ERISA fiduciary claims but let stand the district court’s dismissal of the claim related to plan terms.

    MHPAEA requires that any limitations on “mental health or substance use disorder benefits” in an ERISA plan be “no more restrictive than the predominant treatment limitations applied to substantially all [covered] medical and surgical benefits.” Thus, said the court, to succeed, a plaintiff must show an ERISA plan that offers both M/S and MH/SUD benefits imposed a more restrictive limitation on MH/SUD treatment than limitations on treatment for M/S issues. The court then identified three situations in which such a violation might occur:

    • Facial exclusion cases: A plaintiff can allege that a plan contains an exclusion that is discriminatory on its face.
    • “As-applied” cases: A plaintiff can allege that a plan contains a facially neutral term that is discriminatorily applied to MH/SUD treatment.
    • Internal process cases: A plaintiff can allege that a plan administrator applies an improper internal process that results in the exclusion of an MH/SUD treatment.

    In the court’s view, the complaint raises internal process claims. As such, violations cannot be discerned with reference to the plan document. The court therefore saw no reason to disturb the district court’s dismissal of the claim relating to plan terms.

    With respect to the MHPAEA and ERISA fiduciary claims, the court observed that “fiduciaries must discharge their duties solely in the interests of plan beneficiaries and participants in accordance with the documents and instruments governing the plan insofar as such documents and instruments are consistent with the provisions of” ERISA (emphasis in the original). Thus, said the court, a MHPAEA violation is a breach of fiduciary duty.

    Internal Process Cases Under the Proposed MHPAEA Regulation

    How would internal process claims be treated under the proposed regulations? An internal process that uses an algorithm to assess a patient’s progress and refer the patient’s file for additional review is a “nonquantitative treatment limitation” (NQTL). An NQTL is simply a limitation on the duration and scope of treatment that is expressed in nonnumeric terms limits, e.g., a criterion to determine whether the treatment or services are medical necessity or appropriate. This contrasts with a “quantitative treatment limitation” (QTL), which, as the name suggests, limits the duration and scope of treatment that is expressed in numeric terms, e.g., days in the hospital.

    The proposed rule imposes a new, three-part test under with the internal process would be measured. The test includes a “no more restrictive” requirement, a “design and application” requirement and a “data evaluation” requirement.

    The No More Restrictive Requirement

    A faulty internal process applied only to MH/SUD claims would clearly and immediately run afoul of the “no more restrictive” requirement,” which imposes a numerical test similar to that required under current law that applies to QTLs. Under this test, a plan or issuer may not apply any NQTL to MH/SUD benefits in any classification that is more restrictive than the predominant NQTL that applies to substantially all M/S benefits in the same classification. (The classifications for this purpose are inpatient, in-network; inpatient, out-of-network; outpatient, in-network; outpatient, out-of-network; emergency care; and prescription drugs.)

    The Design and Application Requirement

    Similarly, an improper internal process would as a matter of definition run afoul of the design and application requirement.

    The Data Evaluation Requirement

    Whether an improper internal process would pass muster under the data evaluation requirement will, of course, depend on the data. That said, one might expect that problems in the data would surface on short order.

    Less clear is the application of the proposed regulation’s separate “meaningful benefit” test to an improper internal process. This requirement is a restatement of existing law. It affirms that the requirement to provide MH/SUD coverage in each classification in which M/S benefits are provided applies on a condition or disorder basis. If a plan provides MH/SUD benefits in any classification, it must provide “meaningful [MH/SUD] benefits” in each classification in which it provides M/S benefits. On balance, the meaningful benefit requirement does not appear suited to ferreting out faulty internal processes. Once it is determined that a plan administrator applies an improper internal process to only MH/SUD claims, it would appear to trigger a violation of MHPAEA by definition under both existing law and the proposed regulations. The proposed regulation’s no more restrictive requirement appears to do so in a more targeted fashion. If the facts in Ryan S. are established, and if the proposed regulations are adopted in final, then the “substantially all” fraction for the M/S benefits would be zero. One need not bother with the arithmetic to intuit that the internal process in question would unequivocally fail the data evaluation requirement.

    More insights

  • Go Big Red! Nebraska Passes Consumer Data Privacy Law

    Go Big Red! Nebraska Passes Consumer Data Privacy Law

    ARTICLE / CLIENT ALERT

    Go Big Red! Nebraska Passes Consumer Data Privacy Law

    April 18, 2024

    Read time: 7 min

    Key takeaways
    Overview

    Consult our interactive state privacy law map to learn more about all of the enacted state consumer privacy laws.


    On April 12, 2024, the Nebraska Legislature passed the Data Privacy Act (NEDPA), sending the bill to Governor Jim Pillen’s desk for signature.

    NEDPA adds to the patchwork of state consumer privacy laws in that it does not follow what has become the normal Connecticut/Virginia model; rather, it substantively mirrors the Texas Data Privacy and Security Act, which had until this point been an outlier.

    If signed into law, NEDPA would take effect January 1, 2025.

    In depth

    Who Does NEDPA Apply To?

    NEDPA applies to companies that:

    1. Conduct business in Nebraska or produce a product or service consumed by Nebraska residents;
    2. Process or engage in the sale of personal data; and
    3. Are not a small business under the federal Small Business Act.

    As with other state laws, “sale of personal data” means “the exchange of personal data for monetary or other valuable consideration” to a third party. A sale does not, however, include (i) the disclosure of personal data to a processor; (ii) the disclosure to a third party for the purposes of providing a product requested by the consumer; (iii) the disclosure to an affiliate; (iv) the disclosure of information made publicly available by the consumer; or (v) the disclosure as part of a corporate transaction (e.g., merger, acquisition or bankruptcy).

    Who Is a “Consumer”?

    A consumer is a resident of Nebraska acting in an individual or household context and expressly excludes individuals acting in a commercial or employment context.

    What Is “Personal Data”?

    The “personal data” definition is one we have grown accustomed to. It is information that is linked or can be reasonably linked to an identified or identifiable individual, excluding de-identified data or publicly available information. The definition in NEDPA also includes “pseudonymous data when it is used by a controller or processor in conjunction with additional information that reasonably links the data” to an individual.

    Who Can Enforce?

    NEDPA does not create a privacy right of action, and as a result, the Nebraska attorney general has exclusive enforcement authority. NEDPA includes a 30-day cure period prior to the commencement of any action. Statutory penalties up to $7,500 per violation can be imposed.

    Who Is Exempt?

    NEDPA has several entity-level exemptions, including for:

    • State agencies or political subdivisions of Nebraska;
    • Financial institutions or affiliates subject to the Gramm-Leach-Bliley Act;
    • Covered entities or business associates regulated under the Health Insurance Portability and Accountability Act (HIPAA);
    • Nonprofit organizations;
    • Colleges or universities; and
    • Electricity and natural gas public utilities.

    NEDPA’s list of data-level exemptions is fairly standard, including data processed in accordance with a variety of federal laws, such as HIPAA, federal research laws and regulations (such as the Common Rule), the Fair Credit Reporting Act, the Driver’s Privacy Protection Act, the Family Educational Rights and Privacy Act and the Farm Credit Act, among others.

    What Obligations Are Imposed?

    Controllers under NEDPA are subject to a number of obligations, which should be familiar at this point, including requirements to:

    1. Post a public privacy policy that contains the typical disclosures (e.g., what is collected, the categories of third parties to whom data may be disclosed and how to exercise consumer rights);
    2. Minimize the data they collect to what is reasonably necessary for the purpose;
    3. Refrain from using the data they collect for alternative purposes, unless consumer consent is obtained;
    4. Refrain from discriminating against a consumer for exercising their consumer rights;
    5. Obtain consent before processing sensitive data;
    6. Disclose the process and manner of opting out of the sale or share of their personal data to a third party;
    7. Conduct data protection assessments if the processing involves targeted advertising, the sale of personal data, processing sensitive data or presents a reasonably foreseeable risk of substantial injury to the consumer; and
    8. Recognize global opt-out signals.

    What Consumer Rights Are Created by NEDPA?

    NEDPA grants a standard suite of consumer rights to Nebraska residents:

    1. The right to confirm whether or not the controller is processing the consumer’s personal data and to access that data, if being processed;
    2. The right to correct inaccuracies in personal data, considering the nature of the personal data and the purposes for processing the personal data;
    3. The right to require the controller to delete personal data provided by or obtained about the consumer;
    4. The right to data portability when data processing is done through automated means and the data is available in a digital format;
    5. Opt-out rights for targeted advertising, the sale of personal data and profiling, where profiling is being used to produce a legal or similarly significant effect; and
    6. The right to appeal rights requests that have not been fulfilled.

    Sensitive Data

    NEDPA’s definition of sensitive data is slightly narrower than other states, and it includes:

    • Racial or ethnic origin, religious beliefs, mental or physical health diagnosis, sexual orientation, or citizenship/immigration status;
    • Genetic data or biometric data processed for the purpose of uniquely identifying an individual;
    • Personal data collected from a known child (under 13 years of age); or
    • Precise geolocation data (within a 1,750-foot radius).

    Response to Consumer Requests

    NEDPA follows most other states, requiring controllers to respond 45 days after receiving a data subject request. A 45-day extension is available, if reasonably necessary. If a consumer request is denied, the controller must provide an appeal method. The appeal decision must be made within 60 days of receiving the appeal. If an appeal is denied, the decision must include a method for the consumer to submit a complaint with the attorney general.

    Data Protection Assessments

    NEDPA requires controllers to conduct data protection assessments when companies engage in the following processing activities:

    1. Processing personal data for targeted advertising;
    2. Selling personal data;
    3. Processing sensitive data;
    4. Processing personal data for the purposes of profiling, where such profiling presents a reasonably foreseeable risk of unfair, abusive or deceptive treatment of consumers; financial, physical or reputational injury to consumers; intrusion to the private affairs of consumers if it would be offensive to a reasonable person; or results in other substantial injury to consumers; or
    5. Involves personal data that presents a heightened risk of harm to consumers.

    The assessments must identify and weigh the benefits, both direct and indirect, against the potential risks to the consumer. Factors like using de-identified data and the reasonable expectations of consumers must be folded into the analysis. Like other state privacy laws, NEDPA allows impact assessments performed for other state privacy laws to satisfy its assessment requirements.

    When Does NEDPA Take Effect?

    Assuming it is signed into law, NEDPA will go into effect on January 1, 2025.

    ***

    It is increasingly complex to navigate the requirements of 17 state consumer privacy laws now in effect or coming online in the next two years. If you have questions or need assistance in readiness work for the new state consumer laws, please contact your regular McDermott lawyer or reach out to David Saunders or John Ying.

    Authors

    David P. Saunders

    Partner

    Chicago

    More insights

  • Fifth Circuit Rejects Recruiter’s Trade Secret Misappropriation and Contract Defenses

    Fifth Circuit Rejects Recruiter’s Trade Secret Misappropriation and Contract Defenses

    ARTICLE

    Fifth Circuit Rejects Recruiter’s Trade Secret Misappropriation and Contract Defenses

    Apr 18, 2024

    Read time: 3 min

    Key takeaways
    Overview

    The US Court of Appeals for the Fifth Circuit affirmed a district court’s decision finding trade secret misappropriation and breach of contract based on a recruiter’s improper use of confidential client information. Counsel Holdings, Incorporated v. Jowers, Case No. 22-50936 (5th Cir. Apr. 1, 2024) (King, Ho, Engelhardt, JJ.) (per curiam).

    In April 2006, Evan Jowers was hired by MWK (whose successor is Counsel Holdings) as a legal recruiter. Jowers signed an employment agreement with noncompete and nonsolicitation covenants. During his employment, Jowers relocated to Hong Kong, where he began recruiting for law firms in Asia. Jowers resigned from MWK in December 2006, after which he began working for another recruiting firm in Hong Kong called Legis Ventures.

    MWK sued Jowers for trade secret misappropriation and breach of the restrictive covenants in the employment contract. MWK alleged that while Jowers was still employed with MWK, he submitted its candidates for employment through Legis Ventures. After a bench trial, the district court found in favor of MWK on both claims. As to the trade secret claim, the district court concluded that MWK’s customers’ “names, their clients, how much their practices were worth, their language skills, their goals for switching firms, and their law school records” constituted trade secrets. As for the contract claim, the district court found that enforcement of the restrictive covenants was justified because MWK’s client information was a legitimate business interest. Jowers appealed.

    The Fifth Circuit affirmed. As to the trade secret claim, the Court explained that Jowers’s employment agreement explicitly required confidentiality and that MWK’s customers requested that Jowers keep their information secret. Despite the restrictions, Jowers divulged MWK’s customer information to others, including a competing recruitment firm, without authorization. The Fifth Circuit agreed with the district court’s determination that Jowers’s actions constituted trade secret misappropriation.

    As to the breach of contract claim, Jowers argued that MWK lacked a “legitimate business interest.” The Fifth Circuit found no clear error with the district court’s determination that MWK’s client information was a legitimate business interest that justified enforcement of the restrictive covenant.

    Authors

    Amol Parikh

    Partner

    Chicago

    More insights
    Endnotes

  • New Compliance Obligations for PACE Organizations Coming in 2025

    New Compliance Obligations for PACE Organizations Coming in 2025

    ARTICLE / CLIENT ALERT

    New Compliance Obligations for PACE Organizations Coming in 2025

    April 17, 2024

    Read time: 6 min

    Key takeaways
    Overview

    On April 4, 2024, the Centers for Medicare & Medicaid Services (CMS) issued a final rule and press release revising the regulations governing the Medicare Advantage (MA) Program, Medicare Prescription Drug Benefit Program, and Programs of All-Inclusive Care for the Elderly (PACE). The final rule addresses policy and technical changes for contract year (CY) 2025 and finalizes several key provisions that were first proposed – but never finalized – in a proposed rule originally published on December 14, 2022. The final rule includes significant changes for Medicare Advantage plans, including revisions to permissible payment structures for agents and brokers, supplemental benefits, utilization management and more. The rule also includes meaningful new compliance obligations for PACE organizations, as discussed here.

    McDermott hosted a webinar discussing the PACE policies announced in the final rule on Monday, April 22, 2024. Learn more about the webinar, “Medicare Advantage and Part D Final Rule: New Requirements for PACE.”

    In depth

    PACE Organizations Must Quickly Arrange for the Provision of Approved Clinical Services and Prescribed Medications

    PACE organizations are unique in that they not only approve the healthcare items and services needed by a participant, but they are also responsible for arranging for the provision of those services. Federal regulations require PACE organizations to provide participants access to care 24 hours a day, every day of the year. However, current regulations do not include specific timeframes for service delivery.

    The final rule will add new requirements for PACE organizations regarding arranging and scheduling services. Specifically, PACE organizations must:

    • Arrange and schedule the dispensing of medications as expeditiously as the participant’s condition requires, but no later than 24 hours after the primary care provider orders the medication.
    • Arrange or schedule all other services that are approved by the participant’s care team as expeditiously as the participant’s health condition requires, but no later than seven calendar days after the date the interdisciplinary care team (IDT) or a member of the IDT first approves the service.

    These timeframes apply only to the arranging and scheduling of services, and do not mandate that services actually be delivered within these timeframes. Routine or preventive services will be excluded from the seven-day requirement when certain conditions are met.

    IDTs Must Update Care Plans More Frequently

    IDTs made up of primary care physicians, social workers, home-care coordinators, and other providers and support personnel are a core element of the PACE care delivery model. Each PACE participant must have an IDT that is tasked with implementing, coordinating and monitoring the participant’s plan of care. The plan of care is intended to capture the participant’s medical, physical, social and emotional needs, and to be a comprehensive, living document. CMS is implementing new requirements to encourage IDTs to more frequently revisit and revise the plan of care to incorporate up-to-date information about the participant’s health status and changing needs.

    Specifically, the final rule requires IDTs to:

    • Develop and revise plans of care for each participant.
    • Take into consideration the most current assessment findings and identify services to be furnished.
    • Reevaluate each plan within 180 days from the date when the previous care plan was finalized.
    • Reevaluate the plan within 14 days after the PACE organization determines, or should have determined, that there has been a change in the participant’s health or psychosocial status.
    • If a participant is hospitalized within 14 days of a change in status, the IDT must reevaluate and revise the plan no later than 14 days after the participant’s date of discharge from the hospital.

    The obligation to update the plan of care based on a situation in which the PACE organization “should have determined” that there was a change in the participant’s status establishes a somewhat ambiguous legal standard for PACE organizations. CMS did not provide additional clarity regarding the intended triggers for a PACE organization to further investigate a participant’s health status, or which individuals’ knowledge may result in an obligation on the part of the PACE organization. PACE organizations may consider implementing contractual obligations and operational processes to ensure compliance with these new requirements.

    Participant Grievances Will Be Subject to a Formal Process and Must Be Resolved Within 30 Days

    PACE organizations must have written safeguards addressing participants’ rights, including processes for grievances and appeals. Currently, PACE organizations have the flexibility to develop their own grievance resolution timeframes and procedures. Expressing concern that this flexibility has created inconsistencies in how PACE organizations handle grievances, CMS has implemented a new, formalized grievance process that will be uniform across organizations. The new rules:

    • Require PACE organizations to establish formal written procedures for identifying and resolving grievances.
    • Clarify which individuals are permitted to submit a grievance.
    • Require that grievance notifications include information on participants’ rights.
    • Require that grievances be resolved as expeditiously as required, but no later than 30 days after the organization has received the grievance.

    Other Notable Changes

    The final rule also implements the following key changes:

    • Past Performance Evaluations: Entities that seek to offer a new PACE program or to expand an existing program will be subject to a past performance review, including consideration of whether the applicant was previously subject to an enrollment or payment sanction, failed to maintain fiscal soundness or exceeded a specific threshold for compliance actions, among other criteria.
    • Substantially Incomplete Applications: Any PACE application that does not include the proper state assurances documentation will be considered incomplete and invalid.
    • Personnel Medical Clearance: PACE organizations must develop and implement a comprehensive medical clearance process for staff with direct participant contact, with minimum conditions that CMS deems acceptable. Alternatively, a PACE organization may conduct individual risk assessments that meet CMS’s criteria.
    • Participant Notification Requirements: PACE organizations must disclose to current and potential PACE participants information related to performance and contract compliance deficiencies.
    • Service Determination Requests: All service requests made by participants and/or caregivers before the development of the participant’s initial plan of care must either be (1) approved and incorporated into the initial plan of care or (2) have a documented rationale for not being approved by the PACE organization.

    Please contact our team with any questions regarding the final rule.

    Authors

    Kate McDonald

    Partner

    Washington, DC

    Emily R. Curran

    Associate

    Washington, DC

    More insights